Aviso de resultados del año completo
08 de abril de 2024
Destino Pharma plc
("Destiny Pharma" o "la Compañía")
Aviso de Resultados del Año Completo y Presentación para Inversionistas
Brighton, Reino Unido - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for the year ended 31 December 2023, on Thursday 25 April 2024.
Chris Tovey, Chief Executive Officer, and Shaun Claydon, Chief Financial Officer, will host a briefing for analysts at 8.30am BST followed by a presentation to all existing and potential shareholders at 11:00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00am BST the day before the meeting, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma
plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.
Para más información, por favor póngase en contacto con:
Destino Pharma plc
Chris Tovey, director ejecutivo
Shaun Claydon, director financiero
44 0 1273 704 440
FTI Consultoría
Ben Atwell / Simon Conway / Michael Trace
+44 0 203 727 1000
Shore Capital (Asesor designado y Broker)
Daniel Bush/James Thomas/Lucy Bowden
+44 0 207 408 4090
Acerca de Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
Para obtener más información sobre la empresa, visite www.destinypharma.com
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.